other material
confidence high
sentiment neutral
materiality 0.85
Quince Therapeutics stockholders approve 2026 equity plans, charter amendment, and Series C conversion proposals
Quince Therapeutics, Inc.
- Stockholders approved the 2026 Equity Incentive Plan with an initial reserve of 821,872 shares plus up to 1,377,845 returning shares, and the 2026 ESPP with 142,045 shares.
- The charter amendment increased authorized common stock from 250,000,000 to 275,000,000 shares and was filed in Delaware on Oct. 6, 2026.
- At the Oct. 6, 2026 special meeting, 611,465 of 1,017,063 outstanding shares, or 60%, were present; all five presented proposals were approved.
- Proposal 1, covering Series C preferred conversion and warrants/options, was approved 180,550 to 5,742, with 162,971 shares excluded; it may result in a change of control under Nasdaq Rule 5635(b).
- The 2026 Plan reserve automatically increases 5% annually from Jan. 1, 2027 through Jan. 1, 2036; the ESPP increases by the lesser of 1% or two times its initial reserve.